Inhibitory effects of antagonists of growth hormone-releasing hormone on growth and invasiveness of PC3 human prostate cancer

Antagonists of growth hormone-releasing hormone inhibit growth of androgen-independent prostate cancer through inactivation of ERK and Akt kinases

(2012) F. G. Rick et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Inhibitory effects of antagonists of growth hormone releasing hormone on experimental prostate cancers are associated with upregulation of wild-type p53 and decrease in p21 and mutant p53 proteins

(2011) Anton Stangelberger et al.   PROSTATE

Control of Advanced Cancer: The Road to Chronicity

(2011) Agustin Lage et al.   International Journal of Environmental Research and Public Health

GHRH antagonists reduce the invasive and metastatic potential of human cancer cell lines in vitro

(2010) Szabolcs Bellyei et al.   CANCER LETTERS

Nuclear localization of vasoactive intestinal peptide (VIP) receptors in human breast cancer

(2010) Ana Valdehita et al.   PEPTIDES

p120ctn and P-Cadherin but Not E-Cadherin Regulate Cell Motility and Invasion of DU145 Prostate Cancer Cells

(2010) Sandra Kümper et al.   PLoS One

The relationship between proangiogenic gene expression levels in prostate cancer and their prognostic value for clinical outcomes

(2010) Ryutaro Mori et al.   PROSTATE

E-cadherin, β-catenin, and ZEB1 in malignant progression of cancer

(2009) Otto Schmalhofer et al.   CANCER AND METASTASIS REVIEWS

Osteopontin induces β-catenin signaling through activation of Akt in prostate cancer cells

(2009) Brian W. Robertson et al.   EXPERIMENTAL CELL RESEARCH

Vasoactive intestinal peptide behaves as a pro-metastatic factor in human prostate cancer cells

(2009) Ana B. Fernández-Martínez et al.   PROSTATE

The assessment of angiogenesis and fibroblastic stromagenesis in hyperplastic and pre-invasive breast lesions

(2008) Kitty Pavlakis et al.   BMC CANCER

Knocking down gene expression for growth hormone-releasing hormone inhibits proliferation of human cancer cell lines

(2008) N Barabutis et al.   BRITISH JOURNAL OF CANCER

RhoC Promotes Metastasis via Activation of the Pyk2 Pathway in Prostate Cancer

(2008) M. Iiizumi et al.   CANCER RESEARCH

Epithelial-Mesenchymal Transition in Breast Cancer Relates to the Basal-like Phenotype

(2008) D. Sarrio et al.   CANCER RESEARCH

New Treatment Approaches for Prostate Cancer Based on Peptide Analogues

(2008) Anton Stangelberger et al.   EUROPEAN UROLOGY

Essential role of p21/waf1 in the mediation of the anti-proliferative effects of GHRH antagonist JMR-132

(2008) Aspasia-Athina Volakaki et al.   JOURNAL OF MOLECULAR ENDOCRINOLOGY

Multiple Cellular Mechanisms Related to Cyclin A1 in Prostate Cancer Invasion and Metastasis

(2008) Barbara Wegiel et al.   JNCI-Journal of the National Cancer Institute

Antioxidant activity of growth hormone-releasing hormone antagonists in LNCaP human prostate cancer line

(2008) N. Barabutis et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Dose-dependent growth inhibition in vivo of PC-3 prostate cancer with a reduction in tumoral growth factors after therapy with GHRH antagonist MZ-J-7-138

(2008) Elmar Heinrich et al.   PROSTATE

Antagonists of growth-hormone-releasing hormone: an emerging new therapy for cancer

(2007) Andrew V Schally et al.   Nature clinical practice. Endocrinology & metabolism